News

Pharmaids Pharmaceuticals Limited will close its trading window for designated persons and their immediate relatives from October 1, 2026, until 48 hours after the declaration of the company’s unaudited financial results for the quarter and half year ended September 30, 2026, in compliance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.

Pharmaids Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 12 August 2026.

Net Loss of Pharmaids Pharmaceuticals reported to Rs 1.81 crore in the quarter ended March 2026 as against net loss of Rs 3.94 crore during the previous quarter ended March 2025. Sales rose 50.52% to Rs 7.18 crore in the quarter ended March 2026 as against Rs 4.77 crore during the previous quarter ended March 2025.For the full year,net loss reported to Rs 11.72 crore in the year ended March 2026 as against net loss of Rs 10.78 crore during the previous year ended March 2025. Sales rose 43.34% to Rs 27.88 crore in the year ended March 2026 as against Rs 19.45 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales7.184.77 51 27.8819.45 43 OPM %-4.74-81.76 --48.53-65.55 - PBDT-0.89-4.84 82 -16.74-14.74 -14 PBT-1.37-5.46 75 -18.76-17.18 -9 NP-1.81-3.94 54 -11.72-10.78 -9 Powered by Capital Market - Live News

Pharmaids Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 29 May 2026.

Pharmaids Pharmaceuticals announced the disinvestment/sale of shareholding in Siri Labvivo Diet (the company`s step-down subsidiary) by Adita Bio Sys (the company`s material subsidiary). Consequent to the completion of the above transaction, Siri Labvivo Diet has ceased to be a subsidiary of Adita Bio Sys and accordingly, has also ceased to be a step-down subsidiary of the Company with effect from 27 March 2026. Powered by Capital Market - Live News